Skip to content

Insider · CIK 0002026411

Keith Anthony Jones

director

Files at HUMA (Humacyte, Inc.). First filing Sep 15, 2026, latest Sep 15, 2026.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$5,620 bought, $0 sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

HUMA: Humacyte, Inc.

HUMAOct 9, 2026 · close 0.41

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
21Weak
HUMAbuy
Humacyte, Inc.
$5,620
10,000 shares
+25%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Sep 14, 2026HUMA
Humacyte, Inc.
POpen-market purchase
Common Stock
+10,000$0.56$5,62050,00027 d ago
Jun 12, 2025HUMA
Humacyte, Inc.
AGrant or award
Stock Options (right to buy)derivative
+80,000$0.00$080,000Jun 16, 2025

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Keith Anthony Jones: insider trades and track record | InsiderTell